examined serum exosomes from 19 patients with AML and 14 healthy controls and found that serum exosomes from patients with AML disrupted NK cell activation by downregulating the expression of NKG2D; this effect reduced the toxicity of NK cells to tumor cells, but interleukin 15 counteracted this inhibitory effect (60). Here, KLRK1 is linked to acute myeloid leukemia.